系统综述:丁型肝炎病毒感染者肝脏相关事件的发生率
该综述检索2000年1月1日至2022年12月14日的数据库及2021至2022年会议论文集,纳入报告≥20例活动性HDV感染成人肝硬化、肝功能失代偿、肝细胞癌、肝移植及肝病相关死亡发生率的32项研究。肝硬化累积发生率为0%-63%,肝功能失代偿为0%-52%,肝细胞癌为0%-19%。
要点
- 肝硬化累积发生率为0%-63%,肝功能失代偿为0%-52%,肝细胞癌为0%-19%。
- 肝移植累积发生率为2%-43%,肝病相关死亡为0%-19%,复合终点为3%-74%。
- 报告肝脏相关结局发生率的研究数量仍有限。
核心结论
- 描述HDV感染者肝脏相关结局发生率的研究数量仍有限,量化肝脏相关事件发生率有助于理解疾病进展并为潜在治疗策略提供信息。
研究设计与样本
- 系统综述,检索2000年1月1日至2022年12月14日的在线数据库及2021至2022年会议论文集。
- 纳入报告肝硬化、肝功能失代偿、肝细胞癌、肝移植或肝病相关死亡发生率的随机对照试验、非随机干预研究和观察性研究,要求≥20例活动性HDV感染成人。
- 共从47篇出版物中的32项独特研究提取数据。
主要发现
- 19项(59%)研究纳入<100例个体,5项纳入≥200例。
- 19项(59%)为回顾性队列研究,其余为前瞻性队列研究(5项)、非随机干预研究(3项)、随机对照试验(3项)或登记/数据库研究(2项)。
- 报告结局最多的是肝功能失代偿(21项)和肝细胞癌(20项),报告最少的是肝硬化(9项)。
- 累积发生率范围:肝硬化0%-63%,肝功能失代偿0%-52%,肝细胞癌0%-19%,肝移植2%-43%,肝病相关死亡0%-19%,复合终点3%-74%。
局限性
- 研究间存在异质性,参与者人群及基线肝病严重程度标志物存在变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis delta virus (HDV) requires hepatitis B virus (HBV) surface antigen to enter hepatocytes. Although HBV/HDV coinfection is the most severe form of viral hepatitis, disease progression and liver-related data are limited. AIMS: To evaluate the characteristics of studies reporting HDV outcomes and the incidence of liver-related events among individuals with HDV. METHODS: We searched online databases from 1 January 2000 to 14 December 2022 and congress proceedings from 2021 to 2022. Randomised controlled trials (RCTs), non-randomised interventional studies and observational studies reporting incidence of cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), liver transplant (LT) and liver-related death in ≥ 20 adults with active HDV infection were included. Study/participant characteristics, cumulative incidence and incidence rates were extracted. RESULTS: Data were extracted from 32 unique studies in 47 publications. While most (n = 19; 59%) studies included < 100 individuals, five included ≥ 200. Most were retrospective cohort (n = 19; 59%), and the remainder were prospective cohort (n = 5), non-randomised interventional (n = 3), RCT (n = 3) or registry/database studies (n = 2). Outcomes reported by the largest numbers of studies were hepatic decompensation (n = 21) and HCC (n = 20); the least reported was cirrhosis (n = 9). Heterogeneity existed in participant populations, with variability in baseline markers of liver disease severity. Consequently, a wide range of cumulative incidence values was observed (cirrhosis, 0%-63%; hepatic decompensation, 0%-52%; HCC, 0%-19%; LT, 2%-43%; liver-related death, 0%-19%; composite endpoint, 3%-74%). CONCLUSIONS: The number of studies describing the incidence of liver-related outcomes among people with HDV remains limited. Quantifying incidence of liver-related events can improve our understanding of disease progression and inform potential treatment strategies. TRIAL REGISTRATION: PROSPERO registration ID: CRD42023386845.
引用
- Telep LE, Roulot DM, Singer AW, et al. Systematic Review: Incidence of Liver-Related Events in People Living With Hepatitis Delta Virus. Aliment Pharmacol Ther. 2025. PMID: 40629550. doi:10.1111/apt.70251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。